Boston Scientific

Boston Scientific Announces U.S. and European Launch of Interlock™ - 35 Fibered IDC™ Occlusion System

Detachable coils for peripheral embolization offer precise placement and control in coiling procedures

NATICK, Mass., June 30, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the immediate U.S. and European launch of its Interlock™ – 35 Fibered IDC™ Occlusion System. Earlier this year, the system received clearance from the U.S. Food and Drug Administration and CE Mark approval for obstructing or reducing blood flow in the peripheral vasculature during embolization procedures.

The Interlock – 35 System consists of a 0.035" detachable coil that features a unique interlocking connection between the coil and delivery wire designed to offer excellent placement control, including the ability to advance, retract and reposition the coil before final deployment in the vessel. The coil is engineered to be accurately and reliably detached by simply pushing the detachment zone beyond the distal end of the 5F delivery catheter. The platinum coil is constructed with a dense network of synthetic fibers, designed to offer excellent thrombogenicity (blockage of blood flow) and rapid stasis.

"Compatibility with 5F catheters allows for placement of larger coils, which can help achieve peripheral embolization with fewer coils, potentially reducing procedure times," said Sally Mitchell, M.D., Professor of Radiology, Surgery and Pediatrics at The Johns Hopkins University School of Medicine in Baltimore, MD. "The Interlock – 35 Coil provides excellent occlusive power while allowing precise retrievable placement, representing a major advantage over standard 0.035" pushable coil technology."

The Interlock – 35 Fibered IDC Occlusion System is available in 31 configurations that include coil lengths from 4 cm to 40 cm, diameters from 3 mm to 20 mm, and three distinct shapes (Cube, 2D Helical and Diamond) to offer physicians greater flexibility to treat diverse vessel anatomy. When combined with Boston Scientific's market-leading 0.018" Interlock Fibered IDC Coils, the Interlock Coil portfolio provides 50 different coils to optimize peripheral embolization procedures.

"The Interlock – 35 Coils offer a significant expansion of our best-in-class peripheral vascular coiling technology," said Joe Fitzgerald, Senior Vice President and President of Boston Scientific's Endovascular Unit. "The user-friendly interlocking arms provide excellent control during coil deployment and detachment. The dense network of fibers provides rapid thrombosis, and the availability of larger and longer coils aid in effective vessel occlusion. This new technology offers interventional radiologists a wider range of options to address clinical and anatomic challenges in treating peripheral vascular embolizations."

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Erik Kopp

508-650-8660 (office)
Media Relations
Boston Scientific Corporation
erik.kopp@bsci.com

Sean Wirtjes
508-652-5305 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com

SOURCE Boston Scientific Corporation
